كليدواژه :
اريتروپويتين نوتركيب انساني , لنفوسيت , آنتي بادي , زيست شناسي
چكيده لاتين :
Erythropoietin was first introduced as a factor of RBC proliferation and differentiation. Since the use of recombinant human eryrthropoietin (rHuEPO) in the treatment of anemic patients has increased in recent years, therefore, much attention has been focused on its effects on the immune system. Therefore, in the present study anti-HLA antibody titer changes in three groups of sensitized rats (20 and 100 [U/Kg) were evaluated following administration of two doses of rHuEPO. For this purpose, rats were presensitized with HLA antigens of human lymphocytes. In this respect, RHuEPO injected subcutaneously two times a week for a period of six weeks. Antibody titers were measured by microlymphocytotoxicity method. The results showed that rHuEPo significantly decreases anti-HLA antibody titer. This decrease could be attributed to a reduction in the number or activity of T and B lymphocytes. This effect may also be interpreted by different dosages of the drug, treatment duration, and/or the level of previous sensitization of rats.
